Drug Science (UK) has selected an African company as its supplier for its medical cannabis-focused clinical research initiative, Project Twenty21. The business in question: MG Health Limited, from the Kingdom of Lesotho. According to the companies, Project Twenty21will target 20,000 U.K.-based patients suffering from chronic pain, anxiety disorder, epilepsy, multiple sclerosis, Post Traumatic Stress Disorder; substance use disorder and Tourette’s Syndrome. Researchers will look into the potential benefits of medical cannabis for the treatment of…

READ MORE: https://www.cannabisculture.com/content/2020/02/04/large-medical-cannabis-patient-study-in-europe-picks-african-company-as-supplier/